80 related articles for article (PubMed ID: 32697811)
1. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
[TBL] [Abstract][Full Text] [Related]
2. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J; Ferguson W; Kraveka JM; Bergendahl G; Clinch T; Lorenzi E; Berry D; Wada RK; Isakoff MS; Eslin DE; Brown VI; Roberts W; Zage P; Harrod VL; Mitchell DS; Hanson D; Saulnier Sholler GL
J Clin Oncol; 2024 Jan; 42(1):90-102. PubMed ID: 37883734
[TBL] [Abstract][Full Text] [Related]
3. Yoga as a non-pharmacologic therapy to reduce dinutuximab-induced pain in patients with neuroblastoma.
Parisio KN; Kulp T; Heil M; Li Y; Dalton K; McGrath M; Carlowicz C; Donnelly M; Bagatell R; Jubelirer T
Pediatr Blood Cancer; 2024 Apr; 71(4):e30845. PubMed ID: 38192171
[TBL] [Abstract][Full Text] [Related]
4. Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.
Galassi L; Rossi M; Lodeserto P; Lenzi M; Borsetti F; Voltattorni M; Farruggia G; Blasi P; Orienti I
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839972
[TBL] [Abstract][Full Text] [Related]
5. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics.
Zhang L; Wang M; Zhu Z; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Mol Ther Nucleic Acids; 2021 Dec; 26():732-748. PubMed ID: 34703655
[TBL] [Abstract][Full Text] [Related]
6. A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.
Zhang L; Wang M; Zhu Z; Ding C; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Int J Nanomedicine; 2021; 16():3217-3240. PubMed ID: 34007175
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
8. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD
Transl Pediatr; 2015 Jul; 4(3):226-38. PubMed ID: 26835380
[TBL] [Abstract][Full Text] [Related]
9. Difluoromethylornithine in cancer: new advances.
Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
[TBL] [Abstract][Full Text] [Related]
10. Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO.
Diccianni MB; Kempińska K; Gangoti JA; Yu AL; Sorkin LS
PLoS One; 2020; 15(7):e0236115. PubMed ID: 32697811
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
12. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.
Merali S; Clarkson AB
Antimicrob Agents Chemother; 1996 Apr; 40(4):973-8. PubMed ID: 8849262
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody.
Xiao WH; Yu AL; Sorkin LS
Pain; 1997 Jan; 69(1-2):145-51. PubMed ID: 9060025
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
